Expanding the Therapeutic Frontier with Bispecific Antibodies
Bispecific antibodies (bsAbs) provide novel mechanisms of action and therapeutic possibilities beyond those achievable with conventional IgG-based antibodies. Their development has accelerated over the past decade, leading to the approval of 14 bsAbs by the end of 2023—11 for oncology indications and 3 for non-oncology uses. These molecules come in various formats, target a wide […]
